Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 4/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | NPY1R | P25929 | 1/20 | 0.38 |
| ▸ | NPY2R | P49146 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | CTSA | P10619 | 2/20 | 0.38 |
| ▸ | UTS2R | Q9UKP6 | 3/20 | 0.37 |
| ▸ | USP1 | O94782 | 1/20 | 0.37 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.36 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 5/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.35 |
| ▸ | FAAH | O00519 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2002171 | 0.84 | NR3C2 (0.38) | TNFHPGDNPY1RNPY2RNPSR1 | |
| SCHEMBL2002174 | 0.84 | NR3C2 (0.38) | TNFHPGDNPY1RNPY2RNPSR1 | |
| SCHEMBL2010243 | 0.82 | NR3C1 (0.46) | TNFHPGDNPY1RNPY2RNPSR1 | |
| SCHEMBL2010238 | 0.82 | NR3C1 (0.46) | TNFHPGDNPY1RNPY2RNPSR1 | |
| SCHEMBL2004849 | 0.76 | CIT (0.41) | CTSANR3C1SQOR | |
| SCHEMBL2003302 | 0.76 | CTSA (0.39) | CTSANR3C1SQOR | |
| SCHEMBL2007136 | 0.72 | NR3C1 (0.50) | HPGDNPY1RNPY2RNPSR1NR3C1 | |
| SCHEMBL2007134 | 0.72 | NR3C1 (0.50) | HPGDNPY1RNPY2RNPSR1NR3C1 | |
| SCHEMBL16321909 | 0.72 | TNF (0.58) | TNFHPGDNPY1RNPY2RNPSR1 | |
| SCHEMBL16321910 | 0.72 | TNF (0.58) | TNFHPGDNPY1RNPY2RNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960365-B2 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | N.V. ORGANON (NL) | 2011-06-14 | — | — | US | disclosed |
| EP-1965785-A1 | COMPOUNDS WITH MEDICINAL EFFECTS DUE TO INTERACTION WITH THE GLUCOCORTICOID RECEPTOR | N.V. Organon (NL) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007071638-A1 | COMPOUNDS WITH MEDICINAL EFFECTS DUE TO INTERACTION WITH THE GLUCOCORTICOID RECEPTOR | N.V. ORGANON (NL) | 2007-06-28 | — | — | WO | disclosed |
| US-20070149577-A1 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | N.V. ORGANON (NL) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149577-A1 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | NR3C1, NR3C2, MC2R | TNF 4032/4885HPGD 1665/4885NPY1R 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.